Home Healthcare Healthcare Services Vaccine Contract Manufacturing Market

Vaccine Contract Manufacturing Market Size, Share & Trends Analysis Report By Scale of Operation (Commercial, Clinical, Preclinical), By Vaccine Type (Sub-attenuated Vaccines, Live-attenuated Vaccines, Inactivated Vaccines, Others), By Service (Fill/Finish, Analytical and QC Studies, Cell/Virus Banking, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Vaccine Contract Manufacturing Market, By Scale of Operation 2022-2034 (USD MILLION/ Units)
    1. Commercial
    2. Clinical
    3. Preclinical
  2. Vaccine Contract Manufacturing Market, By Vaccine Type 2022-2034 (USD MILLION/ Units)
    1. Sub-attenuated Vaccines
    2. Live-attenuated Vaccines
    3. Inactivated Vaccines
    4. Others
  3. Vaccine Contract Manufacturing Market, By Service 2022-2034 (USD MILLION/ Units)
    1. Fill/Finish
    2. Analytical and QC Studies
    3. Cell/Virus Banking
    4. Others
  4. Regional Vaccine Contract Manufacturing Market
    1. North America
      1. North America Vaccine Contract Manufacturing Market By Scale of Operation 2022-2034 (USD MILLION/ Units)
        1. Commercial
        2. Clinical
        3. Preclinical
      2. North America Vaccine Contract Manufacturing Market By Vaccine Type 2022-2034 (USD MILLION/ Units)
        1. Sub-attenuated Vaccines
        2. Live-attenuated Vaccines
        3. Inactivated Vaccines
        4. Others
      3. North America Vaccine Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Fill/Finish
        2. Analytical and QC Studies
        3. Cell/Virus Banking
        4. Others
      4. U.S.
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      5. Canada
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
    2. Europe
      1. Europe Vaccine Contract Manufacturing Market By Scale of Operation 2022-2034 (USD MILLION/ Units)
        1. Commercial
        2. Clinical
        3. Preclinical
      2. Europe Vaccine Contract Manufacturing Market By Vaccine Type 2022-2034 (USD MILLION/ Units)
        1. Sub-attenuated Vaccines
        2. Live-attenuated Vaccines
        3. Inactivated Vaccines
        4. Others
      3. Europe Vaccine Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Fill/Finish
        2. Analytical and QC Studies
        3. Cell/Virus Banking
        4. Others
      4. U.K.
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      5. Germany
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      6. France
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      7. Spain
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      8. Italy
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      9. Russia
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      10. Nordic
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      11. Benelux
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      12. Rest of Europe
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
    3. APAC
      1. APAC Vaccine Contract Manufacturing Market By Scale of Operation 2022-2034 (USD MILLION/ Units)
        1. Commercial
        2. Clinical
        3. Preclinical
      2. APAC Vaccine Contract Manufacturing Market By Vaccine Type 2022-2034 (USD MILLION/ Units)
        1. Sub-attenuated Vaccines
        2. Live-attenuated Vaccines
        3. Inactivated Vaccines
        4. Others
      3. APAC Vaccine Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Fill/Finish
        2. Analytical and QC Studies
        3. Cell/Virus Banking
        4. Others
      4. China
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      5. Korea
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      6. Japan
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      7. India
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      8. Australia
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      9. Singapore
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      10. Taiwan
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      11. South East Asia
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      12. Rest of Asia-Pacific
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
    4. Middle East and Africa
      1. Middle East and Africa Vaccine Contract Manufacturing Market By Scale of Operation 2022-2034 (USD MILLION/ Units)
        1. Commercial
        2. Clinical
        3. Preclinical
      2. Middle East and Africa Vaccine Contract Manufacturing Market By Vaccine Type 2022-2034 (USD MILLION/ Units)
        1. Sub-attenuated Vaccines
        2. Live-attenuated Vaccines
        3. Inactivated Vaccines
        4. Others
      3. Middle East and Africa Vaccine Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Fill/Finish
        2. Analytical and QC Studies
        3. Cell/Virus Banking
        4. Others
      4. UAE
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      5. Turkey
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      6. Saudi Arabia
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      7. South Africa
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      8. Egypt
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      9. Nigeria
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      10. Rest of MEA
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
    5. LATAM
      1. LATAM Vaccine Contract Manufacturing Market By Scale of Operation 2022-2034 (USD MILLION/ Units)
        1. Commercial
        2. Clinical
        3. Preclinical
      2. LATAM Vaccine Contract Manufacturing Market By Vaccine Type 2022-2034 (USD MILLION/ Units)
        1. Sub-attenuated Vaccines
        2. Live-attenuated Vaccines
        3. Inactivated Vaccines
        4. Others
      3. LATAM Vaccine Contract Manufacturing Market By Service 2022-2034 (USD MILLION/ Units)
        1. Fill/Finish
        2. Analytical and QC Studies
        3. Cell/Virus Banking
        4. Others
      4. Brazil
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      5. Mexico
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      6. Argentina
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      7. Chile
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      8. Colombia
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
      9. Rest of LATAM
        1. Commercial
        2. Clinical
        3. Preclinical
        4. Sub-attenuated Vaccines
        5. Live-attenuated Vaccines
        6. Inactivated Vaccines
        7. Others
        8. Fill/Finish
        9. Analytical and QC Studies
        10. Cell/Virus Banking
        11. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.